CB-011 Updated Nov 8
CB-011 development has been discontinued. The next event is the ASH 2026 presentation (Dec 12-15), but it is a look-back on a terminated program. The real stock-moving catalyst is the strategic alternatives process (potential sale/merger of Caribou), which has no announced timeline. Watch for any acquisition or asset-sale announcement from the company's exploration process.
- CB-011 generated strong Phase 1 data: 92% ORR, 75% CR rate, and 91% MRD negativity in BCMA-naive patients at the recommended dose (Nov 2025 data).
- Updated EHA 2026 data showed 83% CR rate and 50% of patients in CR at 15 months, suggesting durability.
- CB-011 received both FDA Fast Track designation (Apr 2023) and RMAT designation (Mar 2026), signaling regulatory interest.
- CB-011 development has been permanently discontinued (Oct 2026), eliminating any future upside from the drug itself.
- Caribou is exploring strategic alternatives including a potential sale, indicating the company could not secure funding to advance its pipeline.
- Multiple analysts downgraded CRBU after the discontinuation announcement (HC Wainwright to Neutral, RBC to Sector Perform, Leerink to Market Perform, Brookline to Hold).